Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day
December 06 2019 - 8:30AM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, today announced that the Company plans to host an R&D
Day on December 17, 2019 at 8am Eastern Time in New York City.
Sangamo executives and scientists will provide updates across the
Company’s clinical and preclinical pipeline of genomic medicine
product candidates, offer perspective on clinical data being
presented at the upcoming American Society of Hematology Annual
Meeting, and provide an overview of the Company’s manufacturing
capabilities to support clinical and commercial supply.
A live webcast of the R&D Day including audio and slides
will be available on the Events and Presentations page of the
Sangamo website. A replay of the event will be archived on the
website.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, ex vivo gene-edited cell
therapy, and in vivo genome editing and gene regulation. For more
information about Sangamo, visit www.sangamo.com.
Sangamo Forward Looking Statements
This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements regarding the Company's
ability to develop and commercialize product candidates to address
genetic diseases with the Company's proprietary technologies, as
well as the timing of commencement of clinical programs and the
anticipated benefits therefrom. These statements are not guarantees
of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, the outcomes of clinical trials, uncertainties
related to clinical trials, and Sangamo's reliance on partners to
meet clinical and manufacturing obligations. Further, there can be
no assurance that the necessary regulatory approvals will be
obtained or that Sangamo and its partners will be able to develop
commercially viable product candidates. Actual results may differ
from those projected in forward-looking statements due to risks and
uncertainties that exist in Sangamo's operations and business
environments. These risks and uncertainties are described more
fully in Sangamo's Annual Report on Form 10-K for the year ended
December 31, 2018 as filed with the Securities and Exchange
Commission and Sangamo's most recent Quarterly Report on Form 10-Q.
Forward-looking statements contained in this announcement are made
as of this date, and Sangamo undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191206005067/en/
Investor Relations – Global McDavid
Stilwell 510-970-6000, x219 mstilwell@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Apr 2023 to Apr 2024